Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.

Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M.

Haemophilia. 2011 Nov;17(6):895-905. doi: 10.1111/j.1365-2516.2011.02534.x. Epub 2011 Apr 27.

PMID:
21535320
2.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
3.

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).

Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; Humate-P Study Group.

Haemophilia. 2004 Jan;10(1):42-51.

PMID:
14962219
4.

Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.

Di Paola J, Lethagen S, Gill J, Mannucci P, Manco-Johnson M, Bernstein J, Nichols WL, Bergman GE.

Haemophilia. 2011 Sep;17(5):752-8. doi: 10.1111/j.1365-2516.2011.02583.x. Epub 2011 Jun 20.

PMID:
21689209
5.

von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.

Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group.

J Thromb Haemost. 2007 Jul;5(7):1420-30. Epub 2007 Apr 16.

6.

Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.

Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada.

Thromb Haemost. 2002 Feb;87(2):224-30.

PMID:
11858481
7.

The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.

Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators.

Thromb Haemost. 2011 Aug;106(2):279-88. doi: 10.1160/TH11-02-0057. Epub 2011 Jul 4.

PMID:
21725579
8.
9.

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.

Windyga J, von Depka-Prondzinski M; European Wilate® Study Group.

Thromb Haemost. 2011 Jun;105(6):1072-9. doi: 10.1160/TH10-10-0631. Epub 2011 Mar 24.

PMID:
21437358
10.

Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.

Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.

Haemophilia. 2010 Jul 1;16(4):615-24. doi: 10.1111/j.1365-2516.2010.02206.x. Epub 2010 Mar 16.

PMID:
20331755
11.

Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.

Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.

Thromb Haemost. 1999 Feb;81(2):229-33.

PMID:
10063997
12.

Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.

Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A.

Acta Haematol. 2009;121(2-3):167-76. doi: 10.1159/000214857. Epub 2009 Jun 8. Review.

PMID:
19506363
13.

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.

Haematologica. 2003 Nov;88(11):1279-83.

14.

Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.

Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A.

Haemophilia. 2008 Jul;14(4):763-7. doi: 10.1111/j.1365-2516.2008.01755.x. Epub 2008 Apr 24.

PMID:
18445014
15.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
16.

Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.

Auerswald G, Kreuz W.

Haemophilia. 2008 Nov;14 Suppl 5:39-46. doi: 10.1111/j.1365-2516.2008.01850.x. Review.

PMID:
18786009
17.

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.

Haemophilia. 2002 Nov;8(6):761-7.

PMID:
12410644
18.

Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.

Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM.

Haematologica. 2007 Jul;92(7):944-51.

19.

Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.

Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M.

Br J Haematol. 1992 Feb;80(2):214-21.

PMID:
1550779
20.

Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.

Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I, Inbal A.

Haemophilia. 2002 Sep;8(5):622-8.

PMID:
12199669
Items per page

Supplemental Content

Write to the Help Desk